Combigene Ab Stock Number Of Shares Shorted

If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.

Based on the recorded statements, Combigene AB has 0.0 of outstending shares currently sold short by investors. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The number of shares shorted for all Sweden stocks is 100.0% higher than that of the company.

The Macroaxis Fundamental Analysis modules help investors analyze Combigene AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Combigene using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Combigene AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

When running Combigene's price analysis, check to measure Combigene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Combigene is operating at the current time. Most of Combigene's value examination focuses on studying past and present price action to predict the probability of Combigene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Combigene's price. Additionally, you may evaluate how the addition of Combigene to your portfolios can decrease your overall portfolio volatility.